NewSquare Capital LLC bought a new stake in Masimo Co. (NASDAQ:MASI) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,845 shares of the medical equipment provider’s stock, valued at approximately $423,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Capital Investment Advisory Services LLC bought a new stake in shares of Masimo in the second quarter valued at $25,000. Financial Gravity Wealth Inc. bought a new stake in shares of Masimo in the second quarter valued at $31,000. Private Capital Group LLC raised its stake in shares of Masimo by 92.1% in the second quarter. Private Capital Group LLC now owns 340 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 163 shares during the period. Pearl River Capital LLC bought a new stake in shares of Masimo in the second quarter valued at $37,000. Finally, NEXT Financial Group Inc raised its stake in shares of Masimo by 172.0% during the 2nd quarter. NEXT Financial Group Inc now owns 544 shares of the medical equipment provider’s stock valued at $81,000 after purchasing an additional 344 shares during the period. Hedge funds and other institutional investors own 83.07% of the company’s stock.
In related news, CEO Joe E. Kiani sold 18,437 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $160.02, for a total transaction of $2,950,288.74. Following the completion of the transaction, the chief executive officer now directly owns 157,678 shares in the company, valued at $25,231,633.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Micah W. Young sold 12,087 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $150.02, for a total value of $1,813,291.74. Following the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $1,500,200. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 96,433 shares of company stock valued at $15,029,735. 11.50% of the stock is owned by company insiders.
Masimo (NASDAQ:MASI) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.03. Masimo had a return on equity of 17.82% and a net margin of 22.15%. The company had revenue of $229.60 million for the quarter, compared to analyst estimates of $222.46 million. During the same period in the previous year, the company posted $0.73 EPS. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, equities analysts anticipate that Masimo Co. will post 3.15 earnings per share for the current year.
MASI has been the topic of a number of analyst reports. BidaskClub lowered Masimo from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 6th. UBS Group boosted their price objective on Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Stifel Nicolaus boosted their price objective on Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, BTIG Research reiterated a “hold” rating on shares of Masimo in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Masimo has a consensus rating of “Buy” and a consensus target price of $159.25.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: Bar Chart
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.